Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 12, 2010, Pages 1195-1203

  Katamura, Yoshio ^a   Aikata, Hiroshi ^a   Hashimoto, Yoshimasa ^a   Kimura, Yuki ^a   Kawaoka, Tomokazu ^a   Takaki, Shintaro ^a   Waki, Koji ^a   Hiramatsu, Akira ^a   Kawakami, Yoshiiku ^a   Takahashi, Shoichi ^a   Kenjo, Masahiro ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Bone metastases; Hepatocellular carcinoma; Radiotherapy; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LIVER CELL CARCINOMA; MALE; NEPHROTOXICITY; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 78649843278     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00729.x     Document Type: Article

References (25)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41: 100-6.
3. Uka K, Aikata H, Takaki S et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42: 845-53.
4. Kamada K, Kitamoto M, Aikata H et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-90.
5. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167: 759-68.
6. Uka K, Aikata H, Takaki S et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-20.
7. Natsuizaka M, Omura T, Akaike T et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005; 20: 1781-7.
8. Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216: 698-703.
9. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005; 25: 261-5.
10. He J, Zeng ZC, Tang ZY et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009; 115: 2710-20.
11. Kaizu T, Karasawa K, Tanaka Y et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998; 93: 2167-71.
12. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
13. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98: 962-9.
14. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869-76.
15. Montella L, Addeo R, Palmieri G et al. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. Cancer Chemother Pharmacol 2010; 65: 1137-43.
16. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002; 64: 275-80.
17. Van Der Linden YM, Lok JJ, Steenland E et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004; 59: 528-37.
18. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
19. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
20. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006; 21: 684-94.
21. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-69.
22. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97: 840-7.
23. Arrington SA, Damron TA, Mann KA, Allen MJ. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 2008; 97: 284-90.
24. Kijima T, Fujii Y, Suyama T et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 2009; 103: 620-4.
25. Nakamura N, Igaki H, Yamashita H et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol 2007; 37: 38-43.